MedTrace Logo

Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles

NCT04758871 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-06-14

No results posted yet for this study

Summary

To investigate the efficacy of dydrogesterone 30 mg compared to micronized vaginal progesterone 800 mg daily for luteal phase support in hormone replacement therapy frozen embryo transfer cycles, as confirmed by visualization of fetal heart activity by pelvic ultrasound assessment of ongoing pregnancy at 12 weeks of gestation.

Conditions

  • Frozen Embryo Transfer
  • Hormone Replacement Therapy
  • Dydrogesterone
  • Infertility, Female

Interventions

DRUG

Dydrogesterone 10 MG Oral Tablet

10 mg three times daily

DRUG

Micronized progesterone

2x 200 mg vaginal tablets two times daily

Sponsors & Collaborators

  • CRG UZ Brussel

    lead OTHER

Principal Investigators

  • Christophe Blockeel · CRG UZ Brussel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-09-11
Completion
2024-06-13

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04758871 on ClinicalTrials.gov